FDA Launches Priority Voucher Program To Expedite Psychedelic Drug Reviews To 1–2 Months For Serious Mental Illness

The U.S. Food and Drug Administration (FDA) announced a new priority voucher program that could reduce drug review timelines to as little as one to two The U.S. Food and Drug Administration (FDA) announced a new priority voucher program that could reduce drug review timelines to as little as one to two months for certain psychedelic therapies targeting serious mental illness (SMI). The initiative follows the April 18, 2026, executive order (EO), Accelerating Medical Treatments For Serious Mental Illness, and was formally announced by the FDA on April 24, 2026.

The EO directs the FDA and Drug Enforcement . . .